Authors: Dippel, EJ Kereiakes, DJ Tramuta, DA Broderick, TM Shimshak, TM Roth, EM Hattemer, CR Runyon, JP Whang, DD Schneider, JF Abbottsmith, CW

Citation: Ej. Dippel et al., Coronary perforation during percutaneous coronary intervention in the era of abciximab platelet glycoprotein IIb/IIIa blockade: An algorithm for percutaneous management, CATHET C IN, 52(3), 2001, pp. 279-286

Authors: Kereiakes, DJ Obenchain, RL Barber, BL Smith, A McDonald, M Broderick, TM Runyon, JP Shimshak, TM Schneider, JF Hattemer, CR Roth, EM Whang, DD Cocks, D Abbottsmith, CW

Citation: Dj. Kereiakes et al., Abciximab provides cost-effective survival advantage in high-volume interventional practice, AM HEART J, 140(4), 2000, pp. 603-610

Authors: Kereiakes, DJ McDonald, M Broderick, T Roth, EM Whang, DD Martin, LH Howard, WL Schneider, J Shimshak, T Abbottsmith, CW

Citation: Dj. Kereiakes et al., Platelet glycoprotein IIb/IIIa receptor blockers: An appropriate-use modelfor expediting care in acute coronary syndromes, AM HEART J, 139(2), 2000, pp. S53-S60

Authors: Kereiakes, DJ Mueller, M Howard, W Lacock, P Anderson, LC Broderick, TM Roth, EM Whang, DD Abbottsmith, CW

Citation: Dj. Kereiakes et al., Efficacy of abciximab induced platelet blockade using a rapid point of care assay, J THROMB TH, 7(3), 1999, pp. 265-275